Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

View:
Post by SkywalkerofLuke on Mar 07, 2023 3:39pm

Recent News

AGN announced last week that its subsidiary Algernon NeuroScience appointed Dr. David L. Brody as a consultant for its clinical research program for the treatment of Traumatic Brain Injury with DMT.


Key highlights


- Washington University site director for the National Football League (NFL) Neurological player care program

- Board-certified neurologist with both a research and a clinical specialization in TBI and neurodegenerative diseases

- Professor of Neurology at the Washington University School of Medicine in St. Louis


AGN Neuro is planning to be the first company globally to investigate DMT for TBI in humans and is working towards a Phase 2 clinical trial in Q4.


https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/177/algernon-neuroscience-appoints-global-tbi-expert-and-former

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities